Ionis Cuts TRYNGOLZA 2026 Sales Guidance to ~$50M as sHTG Launch Lags
IONS is trading near its 52-week low of $38.305 (3.4% below the low).
Summary
Ionis reported Q3 2026 revenue of $243 million and a $0.66 per-share loss, but cut 2026 TRYNGOLZA sales guidance to about $50 million from $100-110 million as the sHTG launch ramps more slowly than planned. Total revenue, operating loss and cash guidance were reaffirmed.
Key Events · Earnings and Guidance · IONS
-
TRYNGOLZA Guidance Cut
Full-year 2026 TRYNGOLZA net product sales guidance lowered to approximately $50 million from $100-110 million, after $9 million of U.S. net sales in Q3 and $41 million in the first nine months.
-
Q3 Revenue and Loss
Total revenue was $243 million versus $157 million a year ago; net loss was $110 million, or $0.66 per share, on 166 million shares.
-
DAWNZERA and Total Guidance Reaffirmed
DAWNZERA posted $37 million of Q3 net sales and remains on track for $110-120 million for 2026; total revenue of $875-900 million, non-GAAP operating loss of $425-475 million and cash above $1.6 billion were all reaffirmed.
-
Cash Falls After Convertible Repayment
Cash, cash equivalents and short-term investments were $1.9 billion at September 30, 2026, down from $2.7 billion at December 31, 2025, primarily on repayment of the 0% convertible notes due April 2026.
Analysis · IONS · Life Sciences
The headline number is the TRYNGOLZA cut: full-year 2026 product sales guidance drops from $100-110 million to roughly $50 million after only $9 million of U.S. net sales in the third quarter. That is the company's first launch in a large indication, so a slower-than-expected ramp pushes out the revenue curve investors were underwriting. The rest of the quarter is steadier — total revenue of $243 million versus $157 million a year ago, DAWNZERA tracking its $110-120 million guidance, and total revenue, non-GAAP operating loss and cash guidance all reaffirmed. With $1.9 billion of cash and short-term investments, funding is not the near-term issue; the question is whether TRYNGOLZA's sHTG trajectory is a launch-timing problem or a demand problem.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IONS was trading at $37.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $38.31 to $86.74. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.